TLDR Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
The article reviews the historical stigma associated with spironolactone use in breast cancer survivors with alopecia, highlighting that concerns about its potential to increase breast cancer risk are unfounded. Initial fears stemmed from a 1975 case series and 1980s animal studies, but subsequent research, including a 2022 systematic review and meta-analysis, has shown no association between spironolactone and breast cancer. Despite the FDA removing breast cancer as a listed adverse effect in 2018, the stigma persists, leading to underutilization of an effective treatment for alopecia in breast cancer survivors. The article advocates for the reconsideration of spironolactone in managing alopecia without fear of cancer recurrence.
13 citations
,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
10 citations
,
September 2021 in “JAMA Dermatology” Different types of persistent hair loss after chemotherapy respond differently to treatments.
13 citations
,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
31 citations
,
September 2020 in “Clinical endocrinology” Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
1 citations
,
February 2025 in “Supportive Care in Cancer” Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.